A phase II trial focusing on individuals with overweight or obesity, coupled with hypertension or dyslipidemia but without T2D, found that cagrilintide (2.4 mg) alongside diet and exercise, led to a 10% body weight reduction compared to 3% with placebo over 26 weeks [99]

Sources: Serum Zinc Concentration in Patients with Alopecia Areata (2023) National Library of Medicine (accessed 12 September 2025) Stress-Related Hair Loss Among the General Population in Al Majma'ah, Saudi Arabia: A Cross-Sectional Study (2023) Cureus (accessed 12 September 2025) Telogen effluvium (2023) British Association of Dermatology (accessed 12 September 2025) Telogen effluvium (hair shedding) (2019) DermNet (accessed 12 September 2025) Telogen effluvium: Symptoms, treatment, and recovery (2024) Medical News Today (accessed 12 September 2025) Tirzepatide Once Weekly for the Treatment of Obesity (2022) New England Journal of Medicine (accessed 12 September 2025) The Role of Vitamins and Minerals in Hair Loss: A Review (2018) Dermatology and Therapy (accessed 12 September 2025) Treatment of insulin resistance with tirzepatide leading to improvement of hair loss (2024) American Academy of Dermatology (accessed 12 September 2025)
The homeostatic force of ghrelin
Ninety-eight adults with obesity between the ages of 18 and 75 were randomly assigned a dose of retatrutide
Stay informed about medication safety by researching the latest updates from reputable sources like the FDA or pharmaceutical companies such as Eli Lilly
The conversation about what to say when requesting GLP-1 options from your provider can make a significant difference in the alternatives presented to you